Healx, a Cambridge, UK-based AI-powered and patient-inspired technology company specializing in treatments for rare diseases, raised $56M in Series B financing.
The round was led by Atomico with participation from Intel Capital, Global Brain and btov Partners and previous investors Balderton Capital, Amadeus Capital Partners, and Jonathan Milner. In conjunction with the funding, Irina Haivas, Principal at Atomico, joined the board of Healx.
The company intends to use the funds to develop its therapeutic pipeline and to launch its global Rare Treatment Accelerator program, including treatments for fragile X syndrome, the leading genetic cause of autism.
Led by Co-Founder and CEO Dr Tim Guilliams, Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Their AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases to deliver data-driven treatment predictions, which shortens the discovery-to-clinic timeline to as little as 24 months.
Combining their technology with patient insights and drug discovery expertise, the company’s mission is to advance 100 rare disease treatments towards the clinic by 2025.